The three methods of ovulation induction in patients with polycystic ovarian syndrome

The comparison of ovulation induction with Clomiphene Citrate, Letrozole and recombinant FSH in patients with polycystic ovarian syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080831001141N31

Enrollment

360

Registered

2020-12-23

Start date

2018-04-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Female infertility, unspecified

Interventions

Intervention 1: Intervention group: The patients in the ovulation induction group with recombinant FSH (r-FSH) will receive 50 IU of r-FSH daily from the third day of the menstrual cycle for 7 days, a

Eligibility

Sex/Gender

Female

Age

20 Years to 37 Years

Inclusion criteria

Inclusion criteria: Infertile women with polycystic ovarian syndrome based on Rotterdam criteria Age 20-37 years Body Mass Index less than 30 Kg/m2 Total Motile Sperm Counts more than one million and normal morphology more than 4% (Husband)

Exclusion criteria

Exclusion criteria: Women with hematologic and autoimmune disorders Couples with chromosomal and genetic abnormalities Women with uterine anomalies Women with uterine and ovaries surgical history Women with endometriosis and adenomyosis Women with hydrosalpinx Women with uterine fibroids Women with recurrent abortion history

Design outcomes

Primary

Measure	Time frame
Live birth rate; live birth is defined in which a live fetus is delivered beyond 20 completed weeks of gestational. Timepoint: Only once; at least 20 weeks after embryo transfer. Method of measurement: Clinical information.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFirouzeh Ghaffari

ROYAN Institute

ghafaryf@yahoo.com+98 21 2356 2647

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026